Continuous Manufacturing of Recombinant Drugs: Comprehensive Analysis of Cost Reduction Strategies, Regulatory Pathways, and Global Implementation
Guardado en:
| Publicado en: | Pharmaceuticals vol. 18, no. 8 (2025), p. 1157-1189 |
|---|---|
| Autor principal: | |
| Publicado: |
MDPI AG
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text + Graphics Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3244049518 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1424-8247 | ||
| 024 | 7 | |a 10.3390/ph18081157 |2 doi | |
| 035 | |a 3244049518 | ||
| 045 | 2 | |b d20250101 |b d20251231 | |
| 084 | |a 231548 |2 nlm | ||
| 100 | 1 | |a Niazi, Sarfaraz K | |
| 245 | 1 | |a Continuous Manufacturing of Recombinant Drugs: Comprehensive Analysis of Cost Reduction Strategies, Regulatory Pathways, and Global Implementation | |
| 260 | |b MDPI AG |c 2025 | ||
| 513 | |a Review | ||
| 520 | 3 | |a The biopharmaceutical industry is undergoing a fundamental transformation from traditional batch manufacturing to continuous manufacturing (CM) for recombinant drugs and biosimilars, driven by regulatory support through the International Council for Harmonization (ICH) Q13 guidance and compelling economic advantages. This comprehensive review examines the technical, economic, and regulatory aspects of implementing continuous manufacturing specifically for recombinant protein production and biosimilar development, synthesizing validated data from peer-reviewed research, regulatory sources, and global implementation case studies. The analysis demonstrates that continuous manufacturing offers substantial benefits, including a reduced equipment footprint of up to 70%, a 3- to 5-fold increase in volumetric productivity, enhanced product quality consistency, and facility cost reductions of 30–50% compared to traditional batch processes. Leading biomanufacturers across North America, Europe, and the Asia–Pacific region are successfully integrating perfusion upstream processes with connected downstream bioprocesses, enabling the fully end-to-end continuous manufacture of biopharmaceuticals with demonstrated commercial viability. The regulatory framework has been comprehensively established through ICH Q13 guidance and region-specific implementations across the FDA, EMA, PMDA, and emerging market authorities. This review provides a critical analysis of advanced technologies, including single-use perfusion bioreactors, continuous chromatography systems, real-time process analytical technology, and Industry 4.0 integration strategies. The economic modeling presents favorable return-on-investment profiles, accompanied by a detailed analysis of global market dynamics, regional implementation patterns, and supply chain integration opportunities. | |
| 610 | 4 | |a Food & Drug Administration--FDA | |
| 651 | 4 | |a United States--US | |
| 651 | 4 | |a Germany | |
| 653 | |a Monoclonal antibodies | ||
| 653 | |a Product quality | ||
| 653 | |a Collaboration | ||
| 653 | |a Real time | ||
| 653 | |a Batch processes | ||
| 653 | |a Process controls | ||
| 653 | |a Biological products | ||
| 653 | |a Pharmaceutical industry | ||
| 653 | |a Capital expenditures | ||
| 653 | |a Batch processing | ||
| 653 | |a Manufacturing | ||
| 653 | |a Cost control | ||
| 653 | |a 19th century | ||
| 653 | |a Product testing | ||
| 773 | 0 | |t Pharmaceuticals |g vol. 18, no. 8 (2025), p. 1157-1189 | |
| 786 | 0 | |d ProQuest |t Research Library | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3244049518/abstract/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text + Graphics |u https://www.proquest.com/docview/3244049518/fulltextwithgraphics/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3244049518/fulltextPDF/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |